Completed PHASE3 INTERVENTIONAL NCT00296504

A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects

An Open-Label Phase III Study to Assess the Long Term Safety Profile of GW433908 Containing Regimens in HIV-1 Infected Subjects

Sponsor: GlaxoSmithKline

Conditions Infection, Human Immunodeficiency Virus

Interventions fosamprenavir (GW433908) ritonavir

Updated 7 times since 2017 Last updated: Apr 11, 2013 Started: Nov 30, 2001 Primary completion: Oct 31, 2010 Completion: Oct 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00296504, this PHASE3 trial focuses on Infection, Human Immunodeficiency Virus and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2001, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Nov 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
ViiV Healthcare

Data source: ViiV Healthcare

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Badajoz, Spain , Barcelona, Spain , Campinas, Brazil , Coimbra, Portugal , Denver, United States , Fort Lauderdale, United States , Fountain Valley, United States , Galveston, United States , Genoa, Italy , Le Kremlin-Bicêtre, France and 11 more locations